Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Novo Nordisk to Double China R&D Staff

Novo Nordisk, a Danish pharmaceutical company, said today it will expand its research and development staff in Beijing, China from 100 to 200 employees by 2015. The additional staff will initially work on new research involving diabetes.

The company says its future research scope in China will be broadened to include pharmacological studies other than diabetes treatments. The China R&D staff is expected to eventually take part in all aspects of drug discovery, to the point of developing drug candidates for clinical studies in humans.

Novo Nordisk says it was the first international pharmaceutical company to establish R&D in China in 1997. Until now, the China research staff has been building up its expertise in protein engineering and purification, as well as immuno-technologies such as  generation and improvement of monoclonal antibodies.

Comments are closed.